User profiles for C. Queralt
 | Queralt CInstitut Català d'Oncologia, IGTP Verified email at ICONCOLOGIA.NET Cited by 13412 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
…, M Sanchez-Ronco, A Drozdowskyj, C Queralt… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
[HTML][HTML] Screening for epidermal growth factor receptor mutations in lung cancer
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
…, C Mayo, P Lianes, C Queralt… - European …, 2011 - Eur Respiratory Soc
Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
poor and more effective treatments are urgently needed. We have evaluated the efficacy of …
Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid …
…, A Garcia-Martinez, MJ Esteban, C Queralt… - …, 2004 - academic.oup.com
Objectives. To investigate proinflammatory cytokine expression in temporal arteries from
patients with giant-cell arteritis (GCA) and to analyse its relationship with the intensity of the …
patients with giant-cell arteritis (GCA) and to analyse its relationship with the intensity of the …
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations
…, E Carcereny, R Porta, B Massuti, C Queralt… - Clinical Cancer …, 2011 - AACR
… (19) Moreover, decreased BRCA1 resulted in increased sensitivity to the DNA cross-linking
agents mitomycin C and cisplatin but not to the antimicrotubule paclitaxel. (20) Experimental (…
agents mitomycin C and cisplatin but not to the antimicrotubule paclitaxel. (20) Experimental (…
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
…, J Souglakos, MS Ronco, C Queralt… - Human molecular …, 2004 - academic.oup.com
… Finally, enhanced BRCA1 expression has been linked to apoptosis through the c-Jun N-terminal
kinase pathway (6), which is activated by cisplatin-induced DNA damage; inhibition of …
kinase pathway (6), which is activated by cisplatin-induced DNA damage; inhibition of …
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory …
… at 37C, … 85C in a slide warmer plaque (Hybrite, Vysis) and left at 37C overnight. The coverslips
were removed and the slides washed in 2× SSC/0.3%NP40 solution for 2 minutes at 72C …
were removed and the slides washed in 2× SSC/0.3%NP40 solution for 2 minutes at 72C …
Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial
N Karachaliou, C Mayo-de las Casas, C Queralt… - JAMA …, 2015 - jamanetwork.com
… C, In the 40 patients with mutations detected in cfDNA who received erlotinib, according to
type of mutation in cfDNA. D, In the 41 patients with the L858R mutation in tissue according to …
type of mutation in cfDNA. D, In the 41 patients with the L858R mutation in tissue according to …
[HTML][HTML] Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
…, JM Vieitez, I Maeztu, JJ Sanchez, C Queralt, C Mayo… - Annals of oncology, 2005 - Elsevier
Background:: North American and Japanese non-small-cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) activation via tyrosine kinase (TK) mutations …
with epidermal growth factor receptor (EGFR) activation via tyrosine kinase (TK) mutations …
[HTML][HTML] Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
Background: Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated
non-small-cell lung cancer (NSCLC) patients. We investigated the association …
non-small-cell lung cancer (NSCLC) patients. We investigated the association …